Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
5 Wholesalers to Be Slapped with 600 Million Yen Surcharges over Kyushu Bid-Rigging Case
The Japan Fair Trade Commission (FTC) is expected to impose surcharges totaling 600 million yen on five wholesalers over their alleged bid-rigging involving drug purchases made in Kyushu by a state-backed hospital system, Japanese media outlets reported. The FTC confirmed…
To read the full story
Related Article
- JCHO Bars 6 Wholesalers from Drug Procurement Bids in Kyushu
March 30, 2023
- JOHAS Follows Suit to Suspend 6 Wholesalers from Future Bids
March 29, 2023
- Six Wholesalers Barred from NHO Bids after FTC Confirms Bid-Rigging
March 28, 2023
- 5 Wholesalers Ordered to Pay 627 Million Yen in Surcharge over Kyushu Bid-Rigging
March 27, 2023
- 6 Wholesalers Raided over Suspected Bid-Rigging in Kyushu
November 10, 2021
REGULATORY
- LDP Pharma Project Team to Compile Roadmap Proposals after Industry Hearings
April 17, 2026
- DPJ Leader to Urge Drug Price Hikes, “Freeze” on Off-Year Revisions
April 17, 2026
- War-Linked Supply Impact Cases Climb to 34 as Japan Steps Up Response
April 17, 2026
- Meiji Pharma Chair Prods Drug Price Hikes as War Drives Up Costs: Diet
April 17, 2026
- Japan Eases Documentation Requirements for Excipients Listed in Foreign Pharmacopoeias
April 17, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…